Publications by authors named "A Samarina"
Background: Raltegravir is an HIV integrase strand transfer inhibitor recommended for use in pregnancy. The aim of this study was to assess risk of birth defects and other suboptimal outcomes following prenatal exposure to raltegravir.
Methods: We used pooled, prospectively-collected individual patient data from studies in the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC).
Objectives: To estimate the probability of long-term nonprogression (LTNP) in the absence of antiretroviral treatment (ART) in children with perinatally acquired HIV, and the impact of LTNP definitions on these estimates.
Design: Analysis of longitudinal routine care data (follow-up to 2016) collected through a collaboration of cohorts of children in routine HIV care across Europe and Thailand.
Methods: LTNP was defined as reaching age 8 years without disease progression (defined as an AIDS diagnosis or immunosuppression based on WHO immunosuppression-for-age thresholds, age-adjusted CD4+z-scores or CD4+ counts).
We evaluated the effectiveness and safety of direct-acting antivirals in adolescents with hepatitis C (HCV)/HIV coinfection using pooled individual patient-level data from 5 European cohorts. Of 122 participants in follow-up from November 2013 to August 2021, 19 were treated <18 years of age; of 15 with HCV RNA available at/after 12 weeks post-treatment, all had sustained virologic response with acceptable safety. This evidence addresses an important gap in knowledge of treatment outcomes in adolescents with HCV/HIV coinfection in real-life settings.
View Article and Find Full Text PDFA high-density single nucleotide polymorphism (SNP) array is essential to enable faster progress in plant breeding for new cultivar development. In this regard, we have developed an Axiom 60K almond SNP array by resequencing 81 almond accessions. For the validation of the array, a set of 210 accessions were genotyped and 82.
View Article and Find Full Text PDFOutcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and Thailand.
Antivir Ther
June 2022
Article Synopsis
- Etravirine (ETR) is used for second or third-line antiretroviral treatment in children with HIV, and a study assessed its outcomes in children across Europe and Thailand.
- Data was collected from 177 children, showing that 69% achieved viral suppression after 12 months and experienced an increase in CD4 cell counts; however, 46% discontinued ETR due to reasons such as treatment simplification and failure.
- Some adverse events were reported, including rare but serious reactions like Stevens-Johnson Syndrome, but overall, ETR proved effective for many treatment-experienced children.